Spotlight On:

Rev. 0.0

TLE1 (1F5)

Synovial sarcomas are rare soft tissue tumors of unknown origin. Synovial sarcomas make up about 8% of all soft tissue neoplasms regardless of age; however, they make up about 15-20% of soft tissue tumors in adolescents and young adults. This makes synovial sarcomas the most common non-rhabdomyosarcoma soft tissue tumors in adolescents and young adults. Synovial sarcomas are challenging to diagnose by pure histology, since the monophasic subtype resembles other spindle cell tumors such as malignant peripheral nerve sheath tumors and fibrosarcomas, and the poorly differentiated synovial sarcomas may resemble other small round blue cell tumors, such as Ewing's sarcoma.

Synovial sarcoma is associated with the chromosomal translocation t(X;18) (p11;q11). Though there are established molecular methods such as cytogenetics and *in situ* hybridization for testing for this translocation, practical considerations create a demand for an IHC test that will label synovial sarcoma. The TLE1 mouse monoclonal antibody has been reported to label the nuclei of synovial sarcomas, and TLE1 was minimally expressed or negative in many mesenchymal tumors that mimic synovial sarcoma (https://www.ncbi.nlm.nih.gov/pubmed/17255769). It is suggested

Synovial sarcoma nuclei are strongly positive for TLE1.


that anti-TLE1 be incorporated into soft tissue neoplasm panels that include synovial sarcoma in the differential diagnosis.

Benefits of TLE1:

- In vitro diagnostic
- Compatible with multiple automated staining platforms
- Allows a more cost effective method for identification of synovial sarcomas than molecular testing
- Aids in distinguishing synovial sarcomas from mimics such as MPNST, fibrosarcomas, hemangiopericytomas, and Ewing's sarcomas/PNETs
- Utilized in an immunohistochemical panel that includes cytokeratin AE1/AE3, EMA, CD34, and BCL2

Ordering Information

0.1 ml concentrate	401M-14
0.5 ml concentrate	401M-15
1 ml concentrate	401M-16
1 ml predilute	401M-17
7 ml predilute	401M-18
5 positive control slides	4015



Rhabdomyosarcomas do not express TLE1.



Phone: +1 916.746.8900 international@cellmarque.com www.cellmarque.com



Theaterstraße 6 Tel. ++49(0)4103/8006-342 D-22880 Wedel Fax ++49(0)4103/8006-359

www.medac-diagnostika.de